The plastic role of dendritic cells (DCs) in the regulation of immune responses has made them interesting targets for immunotherapy, but also for pathogens or tumors to evade immunity. Functional alterations of DCs are often ascribed to manipulation of canonical NF-κB activity. However, though this pathway has been linked to murine myeloid DC biology, a detailed analysis of its importance in human myeloid DC differentiation, survival, maturation, and function is lacking. The myeloid DC subsets include interstitial DCs and Langerhans cells. In this study, we investigated the role of canonical NF-κB in human myeloid DCs generated from monocytes (monocyte-derived DCs [mo-DCs]) or CD34+ progenitors (CD34-derived myeloid DCs [CD34-mDCs]). Inhibition of NF-κB activation during and after mo-DC, CD34-interstitial DC, or CD34-Langerhans cell differentiation resulted in apoptosis induction associated with caspase 3 activation and loss of mitochondrial transmembrane potential. Besides regulating survival, canonical NF-κB activity was required for the acquisition of a DC phenotype. Despite phenotypic differences, however, Ag uptake, costimulatory molecule and CCR7 expression, as well as T cell stimulatory capacity of cells generated under NF-κB inhibition were comparable to control DCs, indicating that canonical NF-κB activity during differentiation is redundant for the development of functional APCs. However, both mo-DC and CD34-mDC functionality were reduced by NF-κB inhibition during activation. In conclusion, canonical NF-κB activity is essential for the development and function of mo-DCs as well as CD34-mDCs. Insight into the role of this pathway may help in understanding how pathogens and tumors escape immunity and aid in developing novel treatment strategies aiming to interfere with human immune responses.

Dendritic cells (DCs) are professional APCs that play a crucial role in the induction of immunity as well as tolerance (1). The DC subtype, its maturation state, and the life span of the Ag-bearing DC together determine the type of the initiated immune response (25). Based on surface markers, localization, functional abilities, and ontogeny, a large variety of DC subsets can be recognized (6).

The myeloid DC subtypes are known for their superior T cell priming ability compared with, for example, plasmacytoid DCs (7). Their ability to induce both immunogenic and tolerogenic immune responses has made them interesting tools for treatment of infections, cancer, autoimmune diseases, and allograft rejection (8). Much research has focused on the active manipulation of DCs, either to augment favorable immunity or to suppress unwanted immune activation (914). Also pathogens and tumors often escape immunity via modulation of DC immunogenicity (1519). In many cases, the functional alterations of DCs by drugs, pathogens, or tumor-derived factors are ascribed to manipulation of NF-κB activity.

NF-κB/Rel transcription factor family members are expressed at relatively high levels in DCs (20). In mammals, they exist as homo- or heterodimers of five distinct proteins including RelA (p65), c-Rel, RelB, NF-κB1 (p50 and its precursor p105), and NF-κB2 (p52 and its precursor p100) (21). All of these proteins have been knocked out in mice, and deficiency of RelB or a combined deficiency of RelA and p50 or c-Rel and p50 all result in DC loss (22, 23). The noncanonical transcription factor RelB has further been shown to have a critical role in DC maturation and immunogenicity (22, 2427). Canonical NF-κB activation, which involves phosphorylation and subsequent degradation of the inhibitory IκB proteins enabling nuclear translocation of RelA, c-Rel, and/or p50 dimers, has also been associated with activation-induced DC maturation and function (2831).

Although knockout studies in mice have elegantly shown a loss of functional DCs in the absence of canonical NF-κB proteins, these experiments cannot be directly translated to the human situation. Furthermore, they do not allow separate analysis of the processes involved in DC biology. The exact mechanisms affected by the loss of NF-κB activity therefore remain undefined. Effects on survival, differentiation, maturation, and function can be investigated independently in vitro. In vivo, DCs develop from CD34+ hematopoietic progenitor cells (HPCs) via subset specific precursors that are present either as direct DC precursors, precursor DCs (pre-DCs), or as immune effector cells with their own function in immunity, such as monocytes (6, 32). To study human DC biology in vitro, DC differentiation from monocytes is the most widely used model (33). To investigate the development of myeloid DC subsets from a less committed progenitor, CD34+ HPCs can be used. Two functionally different myeloid subsets, interstitial DCs (intDCs) and Langerhans cells (LCs), develop from CD34+ HPCs via their respective pre-DCs in independent pathways (34, 35), enabling detailed analysis of this DC developmental route.

Studies investigating canonical NF-κB activation in DC development have mainly focused on mouse DCs and human monocyte-derived DCs (mo-DCs). In the current study, we investigated the importance of canonical NF-κB activity in three different human myeloid DC subtypes: mo-DCs, CD34-derived intDCs, and CD34-derived LCs. A detailed analysis evaluating the role of canonical NF-κB in many different aspects of myeloid DC biology was performed. These data not only confirm previous studies suggesting that canonical NF-κB is involved in mo-DC function, but also show the importance of its activation for the functionality of other human myeloid DC subtypes. Moreover, we provide important information on the crucial role of canonical NF-κB in human myeloid DC differentiation and survival.

Where indicated, the specific canonical NF-κB inhibitors caffeic acid phenethyl ester (CAPE; 10 μg/ml unless indicated differently; Sigma-Aldrich, St. Louis, MO), BAY 11-7082 (BAY; 1 μM unless indicated differently; Calbiochem, Merck, Darmstadt, Germany), or AS602868 (AS; 1 μM unless indicated differently; a kind gift from Dr. I. Adcock, Imperial College London, U.K.) were added to the cultures.

Human monocytes were isolated from buffy coats obtained from healthy donors using Ficoll (GE Healthcare, Uppsala, Sweden) density gradient centrifugation followed by positive selection using anti-CD14–coated microbeads as indicated by the manufacturer (Miltenyi Biotec, Bergish Gladbach, Germany). As described before (36), DCs were generated in 6 d in 6- or 12-well culture plates (Costar, Cambridge, MA) in RPMI 1640 (Invitrogen, Breda, The Netherlands) containing 8% heat-inactivated FBS (Sigma-Aldrich) and penicillin/streptomycin (Invitrogen) supplemented with 10 ng/ml GM-CSF (Bayer HealthCare Pharmaceuticals, Seattle, WA) and 10 ng/ml IL-4 (eBioscience, San Diego, CA).

Umbilical cord blood samples were obtained ex uterine according to legal guidelines. CD34+ hematopoietic progenitor cells were isolated and cultured as described previously (35, 37). In brief, CD34+ cells were isolated from mononuclear fractions through positive selection using anti-CD34–coated microbeads (Miltenyi Biotec) to a purity of 85–98%. After cryopreservation to standardize differentiation, cells were cultured in complete medium containing RPMI 1640 supplemented with 8% heat-inactivated FBS, 10 mM HEPES (Invitrogen), 2 mM l-glutamine (Invitrogen), 50 μM 2-ME (Merck, Darmstadt, Germany), and penicillin/streptomycin. From days 0–6, the cells were cultured in complete medium supplemented with 100 ng/ml GM-CSF, 25 ng/ml stem cell factor (PeproTech, London, U.K.), 2.5 ng/ml TNF-α (R&D Systems, Abingdon, U.K.), and 5% heat-inactivated AB+ pooled human serum (four different donors; Sanquin, Rotterdam, The Netherlands). Then, cells were harvested, washed, and further cultured in complete medium containing only GM-CSF (100 ng/ml). For separate analysis of intDCs and LCs, CD34-derived subset specific precursors (pre-DCs) were sorted using a FACS-Aria (BD Biosciences, Breda, The Netherlands). Control cultures were harvested at day 6, incubated with fluorochrome-conjugated Abs against CD1a (HI149, BD Biosciences) and CD14 (MϕP9, BD Biosciences), life gated, and sorted into CD14+CD1a (pre-intDC) and CD14CD1a+ (pre-LC) fractions.

Ag uptake was analyzed as described before (38, 39). In short, receptor-mediated endocytosis was measured as the cellular uptake of 100 μg/ml dextran-FITC (DextranFITC; 40,000 m.w., Molecular Probes, Invitrogen). Approximately 5 × 104 DC were incubated for 2 h at 37°C in the presence of culture medium containing DextranFITC. Negative controls were incubated with DextranFITC at 4°C. Staining was evaluated by flow cytometry, and Ag uptake was calculated by subtracting staining at 4°C from staining at 37°C.

Terminally differentiated DCs were activated by addition of LPS (100 ng/ml; InvivoGen, San Diego, CA) to the cultures. Alternatively, cells were cocultured with CD40L-transfected L cells (L-CD40L) (40) in a DC/L cell ratio of 4:1. Nontransfected L cells (L-Orient) served as control cells. During activation, cells were incubated in the presence of 10 ng/ml GM-CSF and 10 ng/ml IL-4 (mo-DCs) or 100 ng/ml GM-CSF (CD34-derived myeloid dendritic cells [CD34-mDCs]). Cells and supernatants were analyzed after 48 h.

Responder T cells were isolated from a buffy coat. The mononuclear fraction was incubated with anti-CD15– and anti-CD235–coated microbeads (Miltenyi Biotec) and PE-labeled Abs against CD1c (AD5-8E7, Miltenyi Biotec), CD14, CD19 (J4.119, Beckman Coulter, Woerden, The Netherlands), CD56 (MY31, BD Biosciences), and CD123 (SSDCLY107D2, Beckman Coulter) followed by incubation with anti-PE–coated microbeads (Miltenyi Biotec). T cells were isolated through negative selection according to manufacturer’s instructions (Miltenyi Biotec). Irradiated DCs (mo-DCs, 40 Gy; CD34-mDCs, 30 Gy) were added in graded doses to 15 × 104 (mo-DCs) or 2 × 104 (CD34-mDC) allogeneic T cells in 96-well round-bottom plates in RPMI 1640 containing 8% heat-inactivated FBS and penicillin/streptomycin. Proliferation was quantified by incubation with 1 μCi (37 kBq) [methyl-3H]thymidine (NEN Life Science Products, Boston, MA) during the last 18 h of 6-d cultures.

Surface markers.

For phenotypic analysis, cells were washed in PBS containing 1% BSA, 1% heat-inactivated human serum, and 0.02% NaN3. Labeling of cell surface markers was performed on ice using fluorochrome-conjugated Abs against the following Ags: CD1a, CD14, Langerin/CD207 (DCGM4, Beckman Coulter), DC-specific ICAM-3–grabbing nonintegrin (DC-SIGN; DCN46, BD Biosciences), CD40 (mAB89, Beckman Coulter), CD83 (HB15e, BD Biosciences), CD86 (Fun-1, BD Biosciences), B7-H1 (biotin-conjugated; MIH1, eBioscience), HLA-DR (L243, BD Biosciences), and CCR7 (150503, R&D Systems). Binding of biotin-conjugated Abs was visualized by a second incubation with fluorochrome-conjugated streptavidin (BD Biosciences).

Apoptosis.

Apoptosis was detected by determination of phosphatidyl serine exposure and membrane permeability. Cells were harvested, washed in Annexin buffer (10 mM HEPES, 140 mM NaCl, and 2.5 mM CaCl2 [pH 7.4]), incubated with Annexin V-FITC (BD Biosciences) for 30 min on ice, and subsequently taken up in 1 μg/ml propidium iodide (PI; Sigma-Aldrich).

Mitochondrial transmembrane potential.

Mitochondrial dysfunction was assessed using rhodamine 123 (Calbiochem). Cells were incubated in RPMI 1640 supplemented with 8% heat-inactivated FBS and penicillin/streptomycin at 37°C for 30 min in the presence of 0.1 μg/ml rhodamine 123. Then, cells were washed and taken up in PBS.

Caspase 3 activation.

For intracellular staining of active caspase 3, cells were fixed (15 min) and subsequently permeabilized (5 min) by incubation in fixation medium and permeabilization medium (Fix&Perm, ADG Bio Research, Kaumberg, Austria). Labeling of cleaved caspase 3 was performed on ice by 15 min incubation with FITC-conjugated rabbit anti-active caspase 3 (C92-605, BD Biosciences) in permeabilization medium. Rabbit serum was added to block aspecific labeling.

Assessment.

Assessment was performed using a FACSCalibur or FACSCanto II (BD Biosciences), and data were analyzed using FlowJo software (http://www.flowjo.com; Tree Star, Ashland, OR).

The commercially available ELISA kits for human IL-6, IL-10, IL-12p70, and IFN-γ (eBioscience) were used according to the manufacturer’s instructions. The detection limits of these assays were 2 pg/ml (IL-6 and IL-10) and 4 pg/ml (IL-12p70 and IFN-γ).

Cells were washed in PBS and lysed in NTEP-lysis buffer containing 50 mM Tris (pH 7.9), 150 mM NaCl, 5 mM EDTA, and 0.5% Nonidet P-40 supplemented with 1% Protease Inhibitor Cocktail (Sigma-Aldrich). Protein concentrations were determined by the BCA protein assay (Pierce Chemical, Rockford, IL). Equal amounts of total lysate (20 μg/lane) were separated by 10% SDS-PAGE, transferred to a polyvinylidene fluoride membrane (Millipore, Bedford, MA) and incubated with blocking buffer (PBS, 0.1% Tween, 5% non fat dry milk, 1%BSA) before probing with Ab against IκBα (sc-371, Santa Cruz Biotechnology, Heidelberg, Germany). After subsequent incubation with HRP-conjugated Swine-anti-rabbit Ab (DakoCytomation, Glostrup, Denmark) and Supersignal (Pierce Chemical), blots were exposed to Hyperfilm films (Amersham Biosciences, Buckinghamshire, U.K.) to visualize labeled protein. Equal loading was confirmed by Coomassie blue staining.

The role of canonical NF-κB in human myeloid DC development was first investigated in myeloid DCs generated from monocytes. To investigate the importance of canonical NF-κB transcriptional activity, its activation was inhibited by means of the pharmacological inhibitors CAPE, BAY, or AS. Effective blocking of NF-κB activity by these inhibitors was shown by abolished LPS-induced IκBα degradation and IL-6 production (Fig. 1). Whereas monocytes cultured with GM-CSF and IL-4 acquired a characteristic DC morphology and phenotype (CD14CD1a+DC-SIGN+) within 6 d, inhibition of NF-κB by addition of 10 μg/ml CAPE, 1 μM BAY, or 1 μM AS during differentiation reduced the CD1a expression by day 6 monocyte-derived cells (Fig. 2A, 2B). This effect was dose-dependently reduced when the inhibitors were used at lower concentrations, whereas increased concentrations appeared extremely toxic (Fig. 2C). The induction of DC-SIGN expression was also affected by the inhibitors, whereas monocyte marker CD14 was downregulated in all conditions, and CD40 expression was normal regardless of the presence of NF-κB inhibitors (Fig. 2A, 2B). These data indicate that canonical NF-κB activity is required for complete mo-DC differentiation.

FIGURE 1.

CAPE, BAY, and AS inhibit canonical NF-κB activation. Monocytes were cultured in the presence or absence of 100 ng/ml LPS and in the presence or absence of CAPE, BAY or AS. A, Total cell lysates were produced after 45 min and expression of IκBα was determined. Total protein was stained by Coomassie blue to confirm equal loading (n = 3). B, Supernatants were harvested after 24 h. IL-6 concentration was measured by ELISA. Shown are mean ± SDs of duplicate cultures of a representative experiment (n = 4).

FIGURE 1.

CAPE, BAY, and AS inhibit canonical NF-κB activation. Monocytes were cultured in the presence or absence of 100 ng/ml LPS and in the presence or absence of CAPE, BAY or AS. A, Total cell lysates were produced after 45 min and expression of IκBα was determined. Total protein was stained by Coomassie blue to confirm equal loading (n = 3). B, Supernatants were harvested after 24 h. IL-6 concentration was measured by ELISA. Shown are mean ± SDs of duplicate cultures of a representative experiment (n = 4).

Close modal
FIGURE 2.

Mo-DC differentiation is dependent on NF-κB. CAPE, BAY, AS, or their solvent DMSO was added to mo-DC differentiation cultures at days 0, 2, and 5. A, Day 6 cells were harvested and analyzed for the expression of CD14, CD1a, DC-SIGN, and CD40. Viable cells were gated on forward scatter (FSC)/side scatter (SSC). FACS plots are representative of at least 11 experiments. Specific staining intensities, calculated by subtracting background fluorescence from mean fluorescence intensity (MFI) of cells stained with specific Abs, are indicated in the figure. B, CD1a- and DC-SIGN–specific MFIs were standardized to control. Shown are mean ± SEM from at least 11 independent experiments with different donors. C, CAPE, BAY, or AS were added in increasing concentrations. Day 6 cells were analyzed for the expression of CD1a; specific MFIs were calculated and standardized to control. Mean ± SEM CD1a MFIs are shown (n = 3). *p < 0.05, paired Student t test. Over 95% cell death.

FIGURE 2.

Mo-DC differentiation is dependent on NF-κB. CAPE, BAY, AS, or their solvent DMSO was added to mo-DC differentiation cultures at days 0, 2, and 5. A, Day 6 cells were harvested and analyzed for the expression of CD14, CD1a, DC-SIGN, and CD40. Viable cells were gated on forward scatter (FSC)/side scatter (SSC). FACS plots are representative of at least 11 experiments. Specific staining intensities, calculated by subtracting background fluorescence from mean fluorescence intensity (MFI) of cells stained with specific Abs, are indicated in the figure. B, CD1a- and DC-SIGN–specific MFIs were standardized to control. Shown are mean ± SEM from at least 11 independent experiments with different donors. C, CAPE, BAY, or AS were added in increasing concentrations. Day 6 cells were analyzed for the expression of CD1a; specific MFIs were calculated and standardized to control. Mean ± SEM CD1a MFIs are shown (n = 3). *p < 0.05, paired Student t test. Over 95% cell death.

Close modal

The functional abilities of the cells generated were investigated next. Cells differentiated in the presence of NF-κB inhibitors demonstrated normal endocytosis, as was apparent from the unaffected uptake of DextranFITC (Fig. 3A). Although cells differentiated in the presence of CAPE showed a slightly higher CD86 and HLA-DR expression than control mo-DCs at the end of differentiation (day 6), this difference was lost after two additional days of culture in the absence of inhibitors, resulting in similar costimulatory molecule expression in all conditions (Fig. 3B and data not shown). LPS or CD40L stimulation in the absence of inhibitors induced upregulation of all costimulatory molecules, regardless of the presence of NF-κB inhibitors during differentiation (Fig. 3B). In addition, CCR7 expression could be induced in all conditions (Fig. 3B). When comparing LPS- and CD40L-induced cytokine production by cells differentiated in the presence of any of the three NF-κB inhibitors to cytokine secretion by control mo-DCs, no significant changes were observed due to high interdonor variability (Fig. 3C). Interestingly, however, when cells generated with different NF-κB inhibitors were analyzed together, and the inhibitor-induced alterations in CD1a expression, as typical readout for phenotypic differentiation, were combined with the induced modifications of IL-6, IL-10, or IL-12p70 production, a rather weak but significant correlation was found (Fig. 3C). Although these data suggest that, next to a clear effect on phenotype, differentiation of mo-DCs in the presence of NF-κB inhibitors might also modestly affect their LPS- and CD40L-induced cytokine production, the T cell stimulatory capacity of these cells was not significantly different from mo-DCs generated under control conditions. Both control and LPS-stimulated cells from all differentiation conditions induced similar T cell proliferation in allogeneic MLR (Fig. 3D). Although IFN-γ production by T cells cocultured with LPS-stimulated AS-differentiated cells was reduced compared with the control, overall, no changes in IFN-γ concentrations were observed (Fig. 3D). Thus, although phenotypic differences exist between mo-DCs differentiated in the presence or absence of NF-κB activity, NF-κB inhibition does not prevent the generation of functional APCs.

FIGURE 3.

NF-κB inhibition allows differentiation of functional APC. CAPE, BAY, AS, or their solvent DMSO was added to mo-DC differentiation cultures at days 0, 2, and 5. A, Cells were harvested at day 6, thoroughly washed, and incubated with DextranFITC for 2 h at 37°C. Surface binding was determined by incubation at 4°C. Ag uptake was calculated as MFI 37°C − MFI 4°C. Cell debris, as determined by FSC/SSC, was excluded from the analysis. Data represent mean ± SEM Ag uptake standardized to control (n = 3). B, Day 6 cells were harvested, washed thoroughly, and counted with trypan blue exclusion. Equal cell numbers for all conditions were subsequently stimulated with or without 100 ng/ml LPS or L-CD40L. Cells were harvested after 48 h of stimulation and analyzed for the expression of CD86, HLA-DR, B7H1, and CCR7. Viable cells were gated on FSC/SSC. FACS plots representative of at least three experiments are shown. C, Day 6 cells were harvested, analyzed for CD1a expression by flow cytometry, washed thoroughly, and counted with trypan blue exclusion. Equal cell numbers for all conditions were subsequently stimulated with or without 100 ng/ml LPS or L-CD40L. Supernatants were harvested after 48 h of stimulation and IL-6, IL-10, and IL-12p70 concentrations were determined by ELISA. CD1a expression and cytokine concentration in supernatants were standardized to control. Data for all inhibitors were combined, and the Spearman’s rank correlation coefficient (rs) was calculated. Significance and rs are indicated. Data are derived from three to five experiments. D, Cells were harvested at day 6, washed thoroughly, and used in an allogeneic MLR immediately (n = 3) or after 24 h stimulation with LPS (n = 4). Equal DC/T cell ratios in all conditions were ensured by counting the cells with trypan blue exclusion just prior to coincubation. T cell proliferation was quantified by incubating the cells with [methyl-3H]thymidine during the last 18 h of 6-d cultures. ELISA determined IFN-γ concentration in supernatants harvested at day 5. Proliferation and IFN-γ concentrations were standardized to control. Shown are mean ± SEM proliferation in cultures containing DC and T cells in a 1:30 ratio and mean ± SEM IFN-γ concentrations from cultures containing DC and T cells in a 1:10 ratio. *p < 0.05, paired Student t test.

FIGURE 3.

NF-κB inhibition allows differentiation of functional APC. CAPE, BAY, AS, or their solvent DMSO was added to mo-DC differentiation cultures at days 0, 2, and 5. A, Cells were harvested at day 6, thoroughly washed, and incubated with DextranFITC for 2 h at 37°C. Surface binding was determined by incubation at 4°C. Ag uptake was calculated as MFI 37°C − MFI 4°C. Cell debris, as determined by FSC/SSC, was excluded from the analysis. Data represent mean ± SEM Ag uptake standardized to control (n = 3). B, Day 6 cells were harvested, washed thoroughly, and counted with trypan blue exclusion. Equal cell numbers for all conditions were subsequently stimulated with or without 100 ng/ml LPS or L-CD40L. Cells were harvested after 48 h of stimulation and analyzed for the expression of CD86, HLA-DR, B7H1, and CCR7. Viable cells were gated on FSC/SSC. FACS plots representative of at least three experiments are shown. C, Day 6 cells were harvested, analyzed for CD1a expression by flow cytometry, washed thoroughly, and counted with trypan blue exclusion. Equal cell numbers for all conditions were subsequently stimulated with or without 100 ng/ml LPS or L-CD40L. Supernatants were harvested after 48 h of stimulation and IL-6, IL-10, and IL-12p70 concentrations were determined by ELISA. CD1a expression and cytokine concentration in supernatants were standardized to control. Data for all inhibitors were combined, and the Spearman’s rank correlation coefficient (rs) was calculated. Significance and rs are indicated. Data are derived from three to five experiments. D, Cells were harvested at day 6, washed thoroughly, and used in an allogeneic MLR immediately (n = 3) or after 24 h stimulation with LPS (n = 4). Equal DC/T cell ratios in all conditions were ensured by counting the cells with trypan blue exclusion just prior to coincubation. T cell proliferation was quantified by incubating the cells with [methyl-3H]thymidine during the last 18 h of 6-d cultures. ELISA determined IFN-γ concentration in supernatants harvested at day 5. Proliferation and IFN-γ concentrations were standardized to control. Shown are mean ± SEM proliferation in cultures containing DC and T cells in a 1:30 ratio and mean ± SEM IFN-γ concentrations from cultures containing DC and T cells in a 1:10 ratio. *p < 0.05, paired Student t test.

Close modal

Next to the effects on differentiation, NF-κB inhibition during mo-DC development also resulted in reduced cell yields at day 6 (Fig. 4A), indicating a potential role in the regulation of survival. To investigate this further, mo-DC differentiation cultures were harvested at various time points and analyzed for apoptosis. Induction of apoptosis was clearly shown by increased Annexin V staining of the PI population in inhibitor cultures compared with control at days 2, 3, and 6 (p < 0.05) (Fig. 4B and data not shown). In addition, activation of caspase 3 and reduced mitochondrial transmembrane potential was observed at all time points (Fig. 4C, 4D and data not shown). Together, these data show that NF-κB activation during mo-DC development is required to avoid the induction of apoptosis and ensure cell survival.

FIGURE 4.

Apoptosis induction upon NF-κB inhibition. CAPE, BAY, AS, or DMSO was added to mo-DC differentiation cultures at days 0, 2, and 5. A, At day 6, cells were counted with trypan blue exclusion. Yields were standardized to control cultures. Data shown represent mean ± SEM of at least 10 independent experiments with different donors. B, Cells were harvested at day 2 and analyzed for Annexin V/PI staining. PI cells were gated. Representative FACS plots are shown (n = 4). C, Day 2 cells were analyzed for active caspase 3. Data were standardized to control by subtracting the percentage of positive cells in the control culture from the percentage of positive cells in inhibitor cultures. Mean ± SEM percentages of cells showing active caspase 3 are shown (n = 4). D, Day 2 cells were analyzed for mitochondrial transmembrane potential (ΔΨm). The percentage of cells with a decreased ΔΨm was determined, and data were standardized to control as in C. Shown are mean ± SEM (n = 4). *p < 0.05, paired Student t test.

FIGURE 4.

Apoptosis induction upon NF-κB inhibition. CAPE, BAY, AS, or DMSO was added to mo-DC differentiation cultures at days 0, 2, and 5. A, At day 6, cells were counted with trypan blue exclusion. Yields were standardized to control cultures. Data shown represent mean ± SEM of at least 10 independent experiments with different donors. B, Cells were harvested at day 2 and analyzed for Annexin V/PI staining. PI cells were gated. Representative FACS plots are shown (n = 4). C, Day 2 cells were analyzed for active caspase 3. Data were standardized to control by subtracting the percentage of positive cells in the control culture from the percentage of positive cells in inhibitor cultures. Mean ± SEM percentages of cells showing active caspase 3 are shown (n = 4). D, Day 2 cells were analyzed for mitochondrial transmembrane potential (ΔΨm). The percentage of cells with a decreased ΔΨm was determined, and data were standardized to control as in C. Shown are mean ± SEM (n = 4). *p < 0.05, paired Student t test.

Close modal

Next, we investigated the importance of NF-κB in the development of other myeloid DC types, the CD34-derived intDCs and LCs. Six days of culture in the presence of CAPE resulted in a large reduction in cell yield (98 ± 2%) (Fig. 5A). Within the viable cells, CAPE abrogated the generation of CD14+CD1a pre-intDCs from CD34+ HPCs, whereas the development of CD14CD1a+ pre-LCs was relatively retained, as observed by flow cytometry 4 and 6 d after the start of culture (Fig. 5B, 5C). The combination of reduced yield and inhibited differentiation resulted in a strong dose-dependent reduction in pre-LC and pre-intDC numbers upon exposure to CAPE (Fig. 5D). These data show an important role for NF-κB in CD34-derived pre-DC development.

FIGURE 5.

NF-κB is required for CD34-derived pre-DC development. CAPE or its solvent DMSO was added to CD34-derived myeloid DC differentiation cultures from day 0. A, Cells were harvested at day 6 and counted with trypan blue exclusion. Yields were standardized to control cultures. Data shown represent mean ± SEM of three independent experiments with different donors. B and C, Cells were harvested at day 4 and 6 and analyzed for the expression of CD1a and CD14. Viable cells were gated on FSC/SSC. Percentages CD14+CD1a pre-intDCs and CD14CD1a+ pre-LCs were determined and standardized to the control at day 6. Representative FACS plots (B) and mean ± SEM percentage pre-DCs (C) are shown (n = 5). D, CAPE was added in increasing concentrations. Cells were harvested at day 6, counted with trypan blue exclusion, and analyzed for the expression of CD1a and CD14. Yields of CD14+CD1a pre-intDCs and CD14CD1a+ pre-LCs were calculated. *p < 0.05, paired Student t test.

FIGURE 5.

NF-κB is required for CD34-derived pre-DC development. CAPE or its solvent DMSO was added to CD34-derived myeloid DC differentiation cultures from day 0. A, Cells were harvested at day 6 and counted with trypan blue exclusion. Yields were standardized to control cultures. Data shown represent mean ± SEM of three independent experiments with different donors. B and C, Cells were harvested at day 4 and 6 and analyzed for the expression of CD1a and CD14. Viable cells were gated on FSC/SSC. Percentages CD14+CD1a pre-intDCs and CD14CD1a+ pre-LCs were determined and standardized to the control at day 6. Representative FACS plots (B) and mean ± SEM percentage pre-DCs (C) are shown (n = 5). D, CAPE was added in increasing concentrations. Cells were harvested at day 6, counted with trypan blue exclusion, and analyzed for the expression of CD1a and CD14. Yields of CD14+CD1a pre-intDCs and CD14CD1a+ pre-LCs were calculated. *p < 0.05, paired Student t test.

Close modal

Next, differentiation of pre-DCs into terminally differentiated DCs was investigated. CAPE was added to FACS-sorted pre-intDCs or pre-LCs to separately examine the two individual subsets. Under control conditions, CD1aCD14+ pre-intDCs differentiated to CD1a+CD14 intDCs via an intermediate CD1a+CD14+ state, which was clearly present 48 h after pre-intDC isolation. In the presence of CAPE, however, CD1a+ cells did not appear (p < 0.01) (Fig. 6A). Forty-eight-hour cultures of pre-LCs resulted in >90% CD1a+ cells in the presence as well as in the absence of CAPE (Fig. 6A). These data suggest that NF-κB activity is required for intDC but not for LC differentiation. However, a significant reduction in viable cells was observed following CAPE treatment of both subsets (Fig. 6B). Already within 24 h, a 50 ± 9% and 54 ± 9% loss of viable cells was observed in intDC and LC cultures, respectively. In the next days, further cell loss became apparent, resulting in only 36 ± 12% and 18 ± 14% cells remaining after 3 d of treatment. Together, these data show that canonical NF-κB regulates differentiation as well as cell numbers during CD34-derived myeloid DC development.

FIGURE 6.

Survival and differentiation of pre-DCs are dependent on NF-κB. CAPE or its solvent DMSO was added to day 6 FACS-sorted pre-intDCs and pre-LCs. Cells were harvested at days 7, 8, or 9, counted with trypan blue exclusion, and analyzed for the expression of CD1a and CD14. A, Viable cells were gated on FSC/SSC. Shown are representative FACS plots from day 8 cultures (n = 3). B, Yields were standardized to the number of cells at start of culture (day 6). Mean ± SEM of at least three experiments are shown. *p < 0.05, paired Student t test.

FIGURE 6.

Survival and differentiation of pre-DCs are dependent on NF-κB. CAPE or its solvent DMSO was added to day 6 FACS-sorted pre-intDCs and pre-LCs. Cells were harvested at days 7, 8, or 9, counted with trypan blue exclusion, and analyzed for the expression of CD1a and CD14. A, Viable cells were gated on FSC/SSC. Shown are representative FACS plots from day 8 cultures (n = 3). B, Yields were standardized to the number of cells at start of culture (day 6). Mean ± SEM of at least three experiments are shown. *p < 0.05, paired Student t test.

Close modal

As opposed to mo-DC cultures that lack proliferation, the observed cell loss in NF-κB inhibited CD34-derived myeloid DC cultures could result from inhibition of proliferation as well as induction of apoptosis. To investigate the role of apoptosis, NF-κB inhibitors CAPE or AS were added to CD34-myeloid DC cultures at various time points. As shown by the increased Annexin V binding (p < 0.05), apoptosis was induced upon NF-κB inhibition during both pre-DC development and terminal DC differentiation (Fig. 7A, 7B). Also, increased caspase 3 activation and loss of mitochondrial transmembrane potential was observed (Fig. 7C, 7D). Thus, the observed reduction of cells upon NF-κB inhibition can at least partly be explained by the induction of apoptosis.

FIGURE 7.

Inhibition of NF-κB leads to apoptosis in developing CD34-derived myeloid DCs. A, CAPE or DMSO was added to CD34-derived myeloid DC differentiation cultures at day 0. Cells were harvested at day 4 and analyzed for apoptosis by Annexin V and PI staining. Representative FACS plots of PI cells are shown (n = 3). B–D, CAPE, AS, or DMSO was added to day 6 pre-DCs. Cells were harvested at day 8 and analyzed for Annexin V/PI staining, active caspase 3, and ΔΨm. Shown are FACS plots showing Annexin V staining of PI cells (B), mean ± SEM percentages of cells showing active caspase 3, standardized to control (C), and mean ± SEM percentages of cells with a decreased ΔΨm, standardized to control (D) (n = 5). Data were standardized to control by subtracting the percentage of positive cells in the control culture from the percentage of positive cells in inhibitor cultures. *p < 0.05, paired Student t test.

FIGURE 7.

Inhibition of NF-κB leads to apoptosis in developing CD34-derived myeloid DCs. A, CAPE or DMSO was added to CD34-derived myeloid DC differentiation cultures at day 0. Cells were harvested at day 4 and analyzed for apoptosis by Annexin V and PI staining. Representative FACS plots of PI cells are shown (n = 3). B–D, CAPE, AS, or DMSO was added to day 6 pre-DCs. Cells were harvested at day 8 and analyzed for Annexin V/PI staining, active caspase 3, and ΔΨm. Shown are FACS plots showing Annexin V staining of PI cells (B), mean ± SEM percentages of cells showing active caspase 3, standardized to control (C), and mean ± SEM percentages of cells with a decreased ΔΨm, standardized to control (D) (n = 5). Data were standardized to control by subtracting the percentage of positive cells in the control culture from the percentage of positive cells in inhibitor cultures. *p < 0.05, paired Student t test.

Close modal

Although we showed that NF-κB activity is required for survival and phenotypic differentiation of myeloid DCs, NF-κB inhibition during differentiation hardly affected the function of the APCs generated. To investigate whether NF-κB inhibition after terminal differentiation affects DC survival or function, CAPE or AS were added to fully differentiated mo-DCs, CD34-intDCs, and CD34-LCs. Apoptosis was induced upon 24- or 48-h culture in the presence of inhibitors (p < 0.05) (Fig. 8A), demonstrating differentiated myeloid DCs also require NF-κB activation to ensure their survival. Mo-DCs, CD34-LCs, and CD34-intDCs could be rescued from inhibitor-induced apoptosis by stimulation with CD40L, whereas LPS only prevented death of mo-DCs and CD34-LCs (data not shown). Both LPS and CD40L stimulation induced maximal expression of CD83, CD86, and HLA-DR in all cell types, independent of the presence or absence of NF-κB inhibitors (Fig. 8B and data not shown). B7H1, which was only expressed by mo-DCs, was also similarly expressed in all conditions. Whereas these data show that NF-κB is redundant for the induction of costimulatory molecule expression, NF-κB inhibition almost completely abrogated the induction of CCR7 expression by mo-DCs as well as CD34-mDCs (p < 0.05) (Fig. 8B), indicating that canonical NF-κB may be involved in the regulation of lymph node migration. Furthermore, inhibition of NF-κB activity significantly reduced 24 and 48 h activation-induced IL-6 and IL-12p70 secretion by all DC types (Fig. 8C and data not shown). In addition, T cell stimulatory capacity of myeloid DCs that were incubated with inhibitors prior to use in MLR was reduced compared with control DCs. Although no difference in T cell proliferation could be detected, the production of IFN-γ was reduced in MLR using DCs pretreated with CAPE or AS (Fig. 9). A similar pattern was observed at earlier time points (data not shown), indicating that the reduced IFN-γ concentrations resulted from reduced secretion rather than a delayed induction of T cell proliferation. Thus, canonical NF-κB activity regulates functional maturation and thereby T cell stimulatory capacity of both mo-DCs and CD34-derived myeloid DCs.

FIGURE 8.

NF-κB is redundant for induction of costimulatory molecules, but not for induction of CCR7 expression or cytokine production. Mo-DCs were differentiated under control conditions until day 6. Control CD34-derived pre-intDCs and pre-LCs were isolated by FACS sort at day 6 and further cultured under control conditions until day 10 (LC) or day 12 (intDC). Terminally differentiated DCs were cultured with or without L-CD40L in the presence of DMSO, CAPE, or AS. A, Cells cultured in the absence of L-CD40L were harvested after 24 (mo-DC) or 48 h (CD34-mDC) and analyzed for Annexin V/PI staining. FACS plots of PI cells are representative of at least three experiments. B, CD40L-stimulated cells were harvested after 48 h and analyzed for the expression of CD83, CD86, HLA-DR, B7H1, and CCR7. Viable cells were gated on FSC/SSC. Representative FACS plots are shown (n = 3). C, Supernatants of CD40L-stimulated cells were harvested after 48 h. IL-6 and IL-12p70 concentrations were determined by ELISA and standardized to control. Mean ± SEM standardized cytokine concentrations of at least three independent experiments with different donors are shown. *p < 0.05, paired Student t test.

FIGURE 8.

NF-κB is redundant for induction of costimulatory molecules, but not for induction of CCR7 expression or cytokine production. Mo-DCs were differentiated under control conditions until day 6. Control CD34-derived pre-intDCs and pre-LCs were isolated by FACS sort at day 6 and further cultured under control conditions until day 10 (LC) or day 12 (intDC). Terminally differentiated DCs were cultured with or without L-CD40L in the presence of DMSO, CAPE, or AS. A, Cells cultured in the absence of L-CD40L were harvested after 24 (mo-DC) or 48 h (CD34-mDC) and analyzed for Annexin V/PI staining. FACS plots of PI cells are representative of at least three experiments. B, CD40L-stimulated cells were harvested after 48 h and analyzed for the expression of CD83, CD86, HLA-DR, B7H1, and CCR7. Viable cells were gated on FSC/SSC. Representative FACS plots are shown (n = 3). C, Supernatants of CD40L-stimulated cells were harvested after 48 h. IL-6 and IL-12p70 concentrations were determined by ELISA and standardized to control. Mean ± SEM standardized cytokine concentrations of at least three independent experiments with different donors are shown. *p < 0.05, paired Student t test.

Close modal
FIGURE 9.

NF-κB inhibition reduces T cell stimulatory capacity. Mo-DCs (A, B) were differentiated under control conditions until day 6 (n = 5). Control CD34-derived pre-intDCs and pre-LCs were isolated by FACS sort at day 6 and further cultured under control conditions until day 10 (LC) (C, D) or day 12 (intDC) (E, F) (n = 3). Terminally differentiated DCs were cultured with 100 ng/ml LPS in the presence of DMSO, CAPE, or AS. Cells were harvested after 24 h, washed thoroughly, and used in an allogeneic MLR. Equal DC/T cell ratios in all conditions were ensured by counting the cells with trypan blue exclusion just prior to coincubation. T cell proliferation was quantified by incubating the cells with [methyl-3H]thymidine during the last 18 h of 6-d cultures. Shown are mean ± SD of triplicate cultures of a representative experiment (A, C, E). ELISA determined IFN-γ concentration in supernatants from the highest DC/T cell ratio, harvested at day 5. Concentrations were standardized to control. Mean ± SEM concentrations are shown (B, D, F). *p < 0.05, paired Student t test.

FIGURE 9.

NF-κB inhibition reduces T cell stimulatory capacity. Mo-DCs (A, B) were differentiated under control conditions until day 6 (n = 5). Control CD34-derived pre-intDCs and pre-LCs were isolated by FACS sort at day 6 and further cultured under control conditions until day 10 (LC) (C, D) or day 12 (intDC) (E, F) (n = 3). Terminally differentiated DCs were cultured with 100 ng/ml LPS in the presence of DMSO, CAPE, or AS. Cells were harvested after 24 h, washed thoroughly, and used in an allogeneic MLR. Equal DC/T cell ratios in all conditions were ensured by counting the cells with trypan blue exclusion just prior to coincubation. T cell proliferation was quantified by incubating the cells with [methyl-3H]thymidine during the last 18 h of 6-d cultures. Shown are mean ± SD of triplicate cultures of a representative experiment (A, C, E). ELISA determined IFN-γ concentration in supernatants from the highest DC/T cell ratio, harvested at day 5. Concentrations were standardized to control. Mean ± SEM concentrations are shown (B, D, F). *p < 0.05, paired Student t test.

Close modal

DCs are crucial in the induction of immunity as well as tolerance. Their development, survival, and maturation all critically influence the regulation of immune responses. Whereas mouse knockout studies have shown a role for the canonical NF-κB pathway in murine myeloid DC biology, a detailed analysis of its function in the different processes of functional human DC development is lacking. The present study investigated the role of canonical NF-κB activity in development and function of three different human myeloid DC subsets. By using several distinct pharmacological inhibitors the risk of observing non–NF-κB–related side effects was minimized. Overall, only minor differences between the inhibitors were apparent. Canonical NF-κB activity was found to regulate differentiation, survival, maturation, and function of mo-DCs as well as CD34-mDCs.

In mice, simultaneous deficiency of p50 and RelA has been shown to result in DC loss, but whether this was caused by inhibited differentiation or survival remained unclear (23). Canonical NF-κB plays a crucial role in antiapoptosis by the induction of antiapoptotic genes (41). Accordingly, its activity has been associated with augmented cell survival in various cell types (4245). In line, in this study, we show that during development of human myeloid DCs, either from monocytes or from CD34+ HPCs, cell survival is strongly dependent on intact canonical NF-κB activation. Also survival of terminally differentiated mo-DCs and CD34-mDCs required NF-κB activity, though the cells could be rescued from inhibitor-induced apoptosis by the simultaneous presence of activation signals. Reduced survival due to decreased NF-κB activity has been described even in the presence of activation stimuli (23, 30, 46, 47), but these discrepancies probably result from differences in species, DC type, or experimental setup. Together, our data clearly show that canonical NF-κB plays a nonredundant role in the regulation of survival of differentiating as well as fully differentiated monocyte- and CD34-derived human myeloid DC.

Although apoptosis is traditionally thought to require caspase activation, caspase-independent apoptosis has also been described (48). In the current study, NF-κB inhibition-induced death was associated with phosphatidyl serine exposure, an archetypal caspase-dependent event (48, 49), and caspase 3 activation. The additional loss of mitochondrial transmembrane potential further implies a role for mitochondria in the induction and/or amplification of NF-κB inhibition-induced apoptosis. This is in accordance with the role of NF-κB in the induction of genes opposing caspase activation (5052), as well as the transcriptional control of Bcl-2 family members (42, 5355), for which an altered balance can lead to pore formation in the mitochondrial outer membrane, resulting in the release of apoptosis-promoting mitochondrial intermembrane space proteins (56).

As shown in this paper, not only survival but also differentiation of mo-DCs and CD34-derived intDCs depends on canonical NF-κB activity. Inhibited differentiation of CD34-derived intDCs upon NF-κB inhibition was demonstrated by the abrogated development of pre-intDCs and the inhibited CD1a acquisition during terminal differentiation. Similarly, the induction of CD1a and DC-SIGN expression on mo-DCs was reduced by specific NF-κB inhibitors, whereas loss of the monocyte marker CD14 occurred regardless of the presence of inhibitors. Reduced expression of differentiation markers was observed even when inhibitor-induced apoptosis was blocked by simultaneous addition of the pan-caspase inhibitor ZVAD-fmk (data not shown), indicating that the reduced differentiation was not merely a side effect of the presence of dying cells or debris. Furthermore, apoptosis induction in developing myeloid DCs is not necessarily associated with inhibited differentiation, as demonstrated in studies using inhibitors of unrelated pathways that affect survival but not differentiation of the developing DCs (39, 57). Thus, canonical NF-κB activation appears to be nonredundant in the differentiation of human myeloid DCs.

Despite their altered phenotype, cells differentiated under NF-κB inhibition showed normal Ag uptake and normal maturation upon TLR triggering or stimulation with T cell-derived signals such as CD40L. Functional analysis of CD34-derived myeloid DCs generated under NF-κB inhibition could not be performed due to massive cell loss, but for mo-DCs, Ag uptake capacity and induction of costimulatory molecules and CCR7 was similar for cells differentiated in the presence or absence of canonical NF-κB activity. When focusing on a single NF-κB inhibitor, cytokine production by mo-DCs generated in the presence of CAPE, BAY, or AS was not significantly different from control mo-DCs. Nevertheless, when combining all experiments and NF-κB inhibitors, a shift in cytokine profile partially related to inhibitor-induced phenotypic alterations could be observed. Although both the reduced expression of CD1a and DC-SIGN, molecules involved in Ag presentation and T cell stimulation (58, 59), and the altered cytokine production profile could influence the induction of T cell responses, no significant changes in allogeneic T cell stimulatory capacity were found. The unchanged T cell stimulatory capacity of mo-DCs generated with CAPE, BAY, or AS seems to be in contrast to the reported tolerogenic role of BAY (28). However, BAY only induced tolerance when it was used at a concentration of 2.5 μM or higher. At these concentrations, but not at the 1 μM concentration used in the current study, BAY also inhibited the noncanonical NF-κB protein RelB (28), a protein of crucial importance for DC immunogenicity. Thus, although noncanonical NF-κB is essential for the development of functional DCs, we show in this study that despite the role of canonical NF-κB proteins in the regulation of survival and phenotypic differentiation, the function of DCs differentiated in the presence of canonical NF-κB inhibitors was similar to control DCs.

As discussed above, canonical NF-κB inhibition during DC differentiation hardly affected the ability to respond to activation-inducing stimuli. The presence of canonical NF-κB inhibitors during activation of mo-DCs or CD34-mDCs, however, clearly inhibited DC function. In addition to previous studies on mouse myeloid DCs and human mo-DCs (30, 31, 6063), the current study demonstrates that not only mo-DCs but also CD34-derived intDCs and LCs show reduced secretion of proinflammatory cytokines IL-6 and IL-12p70 as well as reduced T cell stimulatory capacity upon NF-κB inhibition during activation. The reduced activation-induced CCR7 expression in the presence of NF-κB inhibition could further abrogate DC functionality, as this could affect lymph node migration and hence interaction with T cells. As DC survival was unaffected in these cultures (data not shown), the reduced functionality reflects regulation of DC function by NF-κB, rather than side effects of cell death or reduced cell numbers. Ag uptake capacity was not affected by inhibition of NF-κB (data not shown). The unchanged upregulation of CD83, CD86, HLA-DR, and B7H1 shown in this paper seems contradictory to some studies describing a role of canonical NF-κB in activation-induced upregulation of costimulatory molecules (30, 61, 64), but is in accordance with others (28, 31). These discrepancies could result from differences in experimental setup. It is, however, not unlikely that the canonical NF-κB pathway contributes to the induction of cytokine secretion, costimulatory molecule expression, and chemokine receptor expression to a different extent. Our data suggest that although functional maturation and CCR7 expression of human myeloid DCs is regulated by canonical NF-κB activation, this pathway is redundant for the upregulation of costimulatory molecules.

Several immunomodulatory compounds such as corticosteroids, vitamin D3, and IL-10 have been reported to inhibit human myeloid DC development (36, 6570). In contrast to specific canonical NF-κB inhibitors, addition of these compounds during DC differentiation not only affects the survival and phenotype of the generated cells, but also affects functional differentiation yielding tolerogenic rather than immunogenic DCs (68, 69, 71). Even in direct comparison in the same experiment, dexamethasone, vitamin D3, and IL-10 affected mo-DC functional differentiation much more vigorously than CAPE, BAY, or AS (L. van de Laar, unpublished observations). These data challenge the suggestion that the immunosuppressive function of corticosteroids, vitamin D3, and IL-10 results from modulation of canonical NF-κB activity alone.

Under both steady-state and inflammatory circumstances, DCs are continuously being replenished from different precursors, including monocytes as well as pre-DCs (4, 6). Manipulation of canonical NF-κB activity by drugs, pathogens, or tumors trying to escape immunity will affect development of myeloid DCs from both monocytic and pre-DC precursors, though CD34-derived myeloid DC development seemed to depend even more strongly on intact NF-κB activity. Furthermore, the functionality of differentiated DCs will be affected by interference with NF-κB activity. The importance of NF-κB in all developmental phases of all investigated myeloid DC types implies that inhibition of canonical NF-κB will, at any moment, interfere with DC-induced immune activation, due to reduced DC numbers as well as the inhibition of activation-induced DC functionality. This knowledge might provide an explanation for the strategies used by certain tumors and pathogens to avoid immune recognition and might open up new tools for the invention of better and more specific immune therapies aiming at either enhancing or suppressing immunity.

In conclusion, canonical NF-κB activation is of crucial importance for the development and function of monocyte- as well as CD34-derived human myeloid DCs. Our data not only confirm previous studies suggesting that canonical NF-κB is involved in mo-DC function, but also show the importance of its activation for the functionality of other human myeloid DCs subtypes. Additionally, we show that canonical NF-κB is pivotal for differentiation and survival of human mo-DCs, CD34-intDCs, and CD34-LCs. This fundamental insight into the regulation of DC development and function may help in understanding how tumors and/or pathogens escape immunity and will contribute to the development of novel treatment strategies aiming to interfere with the human immune system.

We thank Dr. I.M. Adcock (Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London, U.K.) for the kind gift of the AS602868 and Dr. W. van Veelen (Department of Gastroenterology and Hepatology, Erasmus MC–University Medical Center, Rotterdam, The Netherlands) for helpful suggestions.

Disclosures The authors have no financial conflicts of interest.

This work was supported by The Netherlands Organisation for Scientific Research (NWO) (NWO VENI Grant 916.66.015 to A.M.W. and NWO VIDI Grant 917.59.329 to H.L.A.J.).

Abbreviations used in this paper:

AS

AS602868

BAY

BAY 11-7082

CAPE

caffeic acid phenethyl ester

CD34-mDC

CD34-derived myeloid dendritic cell

DC

dendritic cell

DC-SIGN

dendritic cell-specific ICAM-3–grabbing nonintegrin

FSC

forward scatter

HPC

hematopoietic progenitor cell

intDC

interstitial dendritic cell

L-CD40L

CD40L-transfected L cells

LC

Langerhans cell

ΔΨm

mitochondrial transmembrane potential

mo-DC

monocyte-derived dendritic cell

PI

propidium iodide

pre-DC

precursor dendritic cell

SSC

side scatter.

1
Banchereau
J.
,
Steinman
R. M.
.
1998
.
Dendritic cells and the control of immunity.
Nature
392
:
245
252
.
2
Hou
W. S.
,
Van Parijs
L.
.
2004
.
A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells.
Nat. Immunol.
5
:
583
589
.
3
Nopora
A.
,
Brocker
T.
.
2002
.
Bcl-2 controls dendritic cell longevity in vivo.
J. Immunol.
169
:
3006
3014
.
4
Shortman
K.
,
Naik
S. H.
.
2007
.
Steady-state and inflammatory dendritic-cell development.
Nat. Rev. Immunol.
7
:
19
30
.
5
Tan
J. K.
,
O’Neill
H. C.
.
2005
.
Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity.
J. Leukoc. Biol.
78
:
319
324
.
6
Naik
S. H.
2008
.
Demystifying the development of dendritic cell subtypes, a little.
Immunol. Cell Biol.
86
:
439
452
.
7
Boonstra
A.
,
Asselin-Paturel
C.
,
Gilliet
M.
,
Crain
C.
,
Trinchieri
G.
,
Liu
Y. J.
,
O’Garra
A.
.
2003
.
Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation.
J. Exp. Med.
197
:
101
109
.
8
Banchereau
J.
,
Schuler-Thurner
B.
,
Palucka
A. K.
,
Schuler
G.
.
2001
.
Dendritic cells as vectors for therapy.
Cell
106
:
271
274
.
9
Figdor
C. G.
,
de Vries
I. J.
,
Lesterhuis
W. J.
,
Melief
C. J.
.
2004
.
Dendritic cell immunotherapy: mapping the way.
Nat. Med.
10
:
475
480
.
10
O’Neill
D. W.
,
Adams
S.
,
Bhardwaj
N.
.
2004
.
Manipulating dendritic cell biology for the active immunotherapy of cancer.
Blood
104
:
2235
2246
.
11
Sato
K.
,
Yamashita
N.
,
Yamashita
N.
,
Baba
M.
,
Matsuyama
T.
.
2003
.
Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse.
Immunity
18
:
367
379
.
12
Zhang
S.
,
Wang
Q.
,
Miao
B.
.
2007
.
Review: dendritic cell-based vaccine in the treatment of patients with advanced melanoma.
Cancer Biother. Radiopharm.
22
:
501
507
.
13
Silk
K. M.
,
Fairchild
P. J.
.
2009
.
Harnessing dendritic cells for the induction of transplantation tolerance.
Curr. Opin. Organ Transplant.
14
:
344
350
.
14
Skarica
M.
,
Wang
T.
,
McCadden
E.
,
Kardian
D.
,
Calabresi
P. A.
,
Small
D.
,
Whartenby
K. A.
.
2009
.
Signal transduction inhibition of APCs diminishes th17 and Th1 responses in experimental autoimmune encephalomyelitis.
J. Immunol.
182
:
4192
4199
.
15
Gringhuis
S. I.
,
den Dunnen
J.
,
Litjens
M.
,
van Het Hof
B.
,
van Kooyk
Y.
,
Geijtenbeek
T. B.
.
2007
.
C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB.
Immunity
26
:
605
616
.
16
Indoh
T.
,
Yokota
S.
,
Okabayashi
T.
,
Yokosawa
N.
,
Fujii
N.
.
2007
.
Suppression of NF-kappaB and AP-1 activation in monocytic cells persistently infected with measles virus.
Virology
361
:
294
303
.
17
Oyama
T.
,
Ran
S.
,
Ishida
T.
,
Nadaf
S.
,
Kerr
L.
,
Carbone
D. P.
,
Gabrilovich
D. I.
.
1998
.
Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells.
J. Immunol.
160
:
1224
1232
.
18
Au
R. Y.
,
Jedlicka
A. E.
,
Li
W.
,
Pekosz
A.
,
Klein
S. L.
.
2010
.
Seoul virus suppresses NF-kappaB-mediated inflammatory responses of antigen presenting cells from Norway rats.
Virology
400
:
115
127
.
19
Vossenkämper
A.
,
Marchès
O.
,
Fairclough
P. D.
,
Warnes
G.
,
Stagg
A. J.
,
Lindsay
J. O.
,
Evans
P. C.
,
Luong
A.
,
Croft
N. M.
,
Naik
S.
, et al
.
2010
.
Inhibition of NF-κB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE.
J. Immunol.
185
:
4118
4127
.
20
Granelli-Piperno
A.
,
Pope
M.
,
Inaba
K.
,
Steinman
R. M.
.
1995
.
Coexpression of NF-kappa B/Rel and Sp1 transcription factors in human immunodeficiency virus 1-induced, dendritic cell-T-cell syncytia.
Proc. Natl. Acad. Sci. USA
92
:
10944
10948
.
21
Karin
M.
,
Ben-Neriah
Y.
.
2000
.
Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.
Annu. Rev. Immunol.
18
:
621
663
.
22
Burkly
L.
,
Hession
C.
,
Ogata
L.
,
Reilly
C.
,
Marconi
L. A.
,
Olson
D.
,
Tizard
R.
,
Cate
R.
,
Lo
D.
.
1995
.
Expression of relB is required for the development of thymic medulla and dendritic cells.
Nature
373
:
531
536
.
23
Ouaaz
F.
,
Arron
J.
,
Zheng
Y.
,
Choi
Y.
,
Beg
A. A.
.
2002
.
Dendritic cell development and survival require distinct NF-kappaB subunits.
Immunity
16
:
257
270
.
24
Martin
E.
,
O’Sullivan
B.
,
Low
P.
,
Thomas
R.
.
2003
.
Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10.
Immunity
18
:
155
167
.
25
Platzer
B.
,
Jörgl
A.
,
Taschner
S.
,
Höcher
B.
,
Strobl
H.
.
2004
.
RelB regulates human dendritic cell subset development by promoting monocyte intermediates.
Blood
104
:
3655
3663
.
26
Li
M.
,
Zhang
X.
,
Zheng
X.
,
Lian
D.
,
Zhang
Z. X.
,
Ge
W.
,
Yang
J.
,
Vladau
C.
,
Suzuki
M.
,
Chen
D.
, et al
.
2007
.
Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference.
J. Immunol.
178
:
5480
5487
.
27
Yang
H.
,
Zhang
Y.
,
Wu
M.
,
Li
J.
,
Zhou
W.
,
Li
G.
,
Li
X.
,
Xiao
B.
,
Christadoss
P.
.
2010
.
Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile.
Inflamm. Res.
59
:
197
205
.
28
Hernandez
A.
,
Burger
M.
,
Blomberg
B. B.
,
Ross
W. A.
,
Gaynor
J. J.
,
Lindner
I.
,
Cirocco
R.
,
Mathew
J. M.
,
Carreno
M.
,
Jin
Y.
, et al
.
2007
.
Inhibition of NF-kappa B during human dendritic cell differentiation generates anergy and regulatory T-cell activity for one but not two human leukocyte antigen DR mismatches.
Hum. Immunol.
68
:
715
729
.
29
Neumann
M.
,
Fries
H.
,
Scheicher
C.
,
Keikavoussi
P.
,
Kolb-Mäurer
A.
,
Bröcker
E.
,
Serfling
E.
,
Kämpgen
E.
.
2000
.
Differential expression of Rel/NF-kappaB and octamer factors is a hallmark of the generation and maturation of dendritic cells.
Blood
95
:
277
285
.
30
Zhou
L. F.
,
Zhang
M. S.
,
Yin
K. S.
,
Ji
Y.
,
Xie
W. P.
,
Cui
X. F.
,
Ji
X. H.
.
2006
.
Effects of adenoviral gene transfer of mutated IkappaBalpha, a novel inhibitor of NF-kappaB, on human monocyte-derived dendritic cells.
Acta Pharmacol. Sin.
27
:
609
616
.
31
Wang
L. C.
,
Lin
Y. L.
,
Liang
Y. C.
,
Yang
Y. H.
,
Lee
J. H.
,
Yu
H. H.
,
Wu
W. M.
,
Chiang
B. L.
.
2009
.
The effect of caffeic acid phenethyl ester on the functions of human monocyte-derived dendritic cells.
BMC Immunol.
10
:
39
.
32
Wu
L.
,
Liu
Y. J.
.
2007
.
Development of dendritic-cell lineages.
Immunity
26
:
741
750
.
33
Sallusto
F.
,
Lanzavecchia
A.
.
1994
.
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
J. Exp. Med.
179
:
1109
1118
.
34
Caux
C.
,
Massacrier
C.
,
Vanbervliet
B.
,
Dubois
B.
,
Durand
I.
,
Cella
M.
,
Lanzavecchia
A.
,
Banchereau
J.
.
1997
.
CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis.
Blood
90
:
1458
1470
.
35
Caux
C.
,
Vanbervliet
B.
,
Massacrier
C.
,
Dezutter-Dambuyant
C.
,
de Saint-Vis
B.
,
Jacquet
C.
,
Yoneda
K.
,
Imamura
S.
,
Schmitt
D.
,
Banchereau
J.
.
1996
.
CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha.
J. Exp. Med.
184
:
695
706
.
36
Woltman
A. M.
,
de Fijter
J. W.
,
Kamerling
S. W.
,
Paul
L. C.
,
Daha
M. R.
,
van Kooten
C.
.
2000
.
The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells.
Eur. J. Immunol.
30
:
1807
1812
.
37
Woltman
A. M.
,
Massacrier
C.
,
de Fijter
J. W.
,
Caux
C.
,
van Kooten
C.
.
2002
.
Corticosteroids prevent generation of CD34+-derived dermal dendritic cells but do not inhibit Langerhans cell development.
J. Immunol.
168
:
6181
6188
.
38
Woltman
A. M.
,
Schlagwein
N.
,
van der Kooij
S. W.
,
van Kooten
C.
.
2004
.
The novel cyclophilin-binding drug sanglifehrin A specifically affects antigen uptake receptor expression and endocytic capacity of human dendritic cells.
J. Immunol.
172
:
6482
6489
.
39
van de Laar
L.
,
Buitenhuis
M.
,
Wensveen
F. M.
,
Janssen
H. L.
,
Coffer
P. J.
,
Woltman
A. M.
.
2010
.
Human CD34-derived myeloid dendritic cell development requires intact phosphatidylinositol 3-kinase-protein kinase B-mammalian target of rapamycin signaling.
J. Immunol.
184
:
6600
6611
.
40
Garrone
P.
,
Neidhardt
E. M.
,
Garcia
E.
,
Galibert
L.
,
van Kooten
C.
,
Banchereau
J.
.
1995
.
Fas ligation induces apoptosis of CD40-activated human B lymphocytes.
J. Exp. Med.
182
:
1265
1273
.
41
Karin
M.
,
Lin
A.
.
2002
.
NF-kappaB at the crossroads of life and death.
Nat. Immunol.
3
:
221
227
.
42
François
S.
,
El Benna
J.
,
Dang
P. M.
,
Pedruzzi
E.
,
Gougerot-Pocidalo
M. A.
,
Elbim
C.
.
2005
.
Inhibition of neutrophil apoptosis by TLR agonists in whole blood: involvement of the phosphoinositide 3-kinase/Akt and NF-kappaB signaling pathways, leading to increased levels of Mcl-1, A1, and phosphorylated Bad.
J. Immunol.
174
:
3633
3642
.
43
Oakley
F.
,
Meso
M.
,
Iredale
J. P.
,
Green
K.
,
Marek
C. J.
,
Zhou
X.
,
May
M. J.
,
Millward-Sadler
H.
,
Wright
M. C.
,
Mann
D. A.
.
2005
.
Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis.
Gastroenterology
128
:
108
120
.
44
Senftleben
U.
,
Li
Z. W.
,
Baud
V.
,
Karin
M.
.
2001
.
IKKbeta is essential for protecting T cells from TNFalpha-induced apoptosis.
Immunity
14
:
217
230
.
45
Lindemans
C. A.
,
Coffer
P. J.
,
Schellens
I. M.
,
de Graaff
P. M.
,
Kimpen
J. L.
,
Koenderman
L.
.
2006
.
Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-kappaB-dependent mechanism.
J. Immunol.
176
:
5529
5537
.
46
Radhakrishnan
S.
,
Nguyen
L. T.
,
Ciric
B.
,
Van Keulen
V. P.
,
Pease
L. R.
.
2007
.
B7-DC/PD-L2 cross-linking induces NF-kappaB-dependent protection of dendritic cells from cell death.
[Published retraction appears in 2010
J. Immunol.
184: 6554.]
J. Immunol.
178
:
1426
1432
.
47
Barbaroux
J. B.
,
Beleut
M.
,
Brisken
C.
,
Mueller
C. G.
,
Groves
R. W.
.
2008
.
Epidermal receptor activator of NF-kappaB ligand controls Langerhans cells numbers and proliferation.
J. Immunol.
181
:
1103
1108
.
48
Tait
S. W.
,
Green
D. R.
.
2008
.
Caspase-independent cell death: leaving the set without the final cut.
Oncogene
27
:
6452
6461
.
49
Martin
S. J.
,
Finucane
D. M.
,
Amarante-Mendes
G. P.
,
O’Brien
G. A.
,
Green
D. R.
.
1996
.
Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity.
J. Biol. Chem.
271
:
28753
28756
.
50
Stehlik
C.
,
de Martin
R.
,
Kumabashiri
I.
,
Schmid
J. A.
,
Binder
B. R.
,
Lipp
J.
.
1998
.
Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis.
J. Exp. Med.
188
:
211
216
.
51
Wang
C. Y.
,
Mayo
M. W.
,
Korneluk
R. G.
,
Goeddel
D. V.
,
Baldwin
A. S.
 Jr
.
1998
.
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.
Science
281
:
1680
1683
.
52
Varfolomeev
E.
,
Vucic
D.
.
2008
.
(Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways.
Cell Cycle
7
:
1511
1521
.
53
Zong
W. X.
,
Edelstein
L. C.
,
Chen
C.
,
Bash
J.
,
Gélinas
C.
.
1999
.
The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis.
Genes Dev.
13
:
382
387
.
54
Chen
C.
,
Edelstein
L. C.
,
Gélinas
C.
.
2000
.
The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L).
Mol. Cell. Biol.
20
:
2687
2695
.
55
Catz
S. D.
,
Johnson
J. L.
.
2001
.
Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer.
Oncogene
20
:
7342
7351
.
56
Youle
R. J.
,
Strasser
A.
.
2008
.
The BCL-2 protein family: opposing activities that mediate cell death.
Nat. Rev. Mol. Cell Biol.
9
:
47
59
.
57
Woltman
A. M.
,
de Fijter
J. W.
,
Kamerling
S. W.
,
van Der Kooij
S. W.
,
Paul
L. C.
,
Daha
M. R.
,
van Kooten
C.
.
2001
.
Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages.
Blood
98
:
174
180
.
58
Cohen
N. R.
,
Garg
S.
,
Brenner
M. B.
.
2009
.
Antigen Presentation by CD1 Lipids, T Cells, and NKT Cells in Microbial Immunity.
Adv. Immunol.
102
:
1
94
.
59
Geijtenbeek
T. B.
,
Torensma
R.
,
van Vliet
S. J.
,
van Duijnhoven
G. C.
,
Adema
G. J.
,
van Kooyk
Y.
,
Figdor
C. G.
.
2000
.
Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses.
Cell
100
:
575
585
.
60
Laderach
D.
,
Compagno
D.
,
Danos
O.
,
Vainchenker
W.
,
Galy
A.
.
2003
.
RNA interference shows critical requirement for NF-kappa B p50 in the production of IL-12 by human dendritic cells.
J. Immunol.
171
:
1750
1757
.
61
Ade
N.
,
Antonios
D.
,
Kerdine-Romer
S.
,
Boisleve
F.
,
Rousset
F.
,
Pallardy
M.
.
2007
.
NF-kappaB plays a major role in the maturation of human dendritic cells induced by NiSO(4) but not by DNCB.
Toxicol. Sci.
99
:
488
501
.
62
Ding
W.
,
Wagner
J. A.
,
Granstein
R. D.
.
2007
.
CGRP, PACAP, and VIP modulate Langerhans cell function by inhibiting NF-kappaB activation.
J. Invest. Dermatol.
127
:
2357
2367
.
63
Tas
S. W.
,
de Jong
E. C.
,
Hajji
N.
,
May
M. J.
,
Ghosh
S.
,
Vervoordeldonk
M. J.
,
Tak
P. P.
.
2005
.
Selective inhibition of NF-kappaB in dendritic cells by the NEMO-binding domain peptide blocks maturation and prevents T cell proliferation and polarization.
Eur. J. Immunol.
35
:
1164
1174
.
64
Temmerman
S. T.
,
Ma
C. A.
,
Borges
L.
,
Kubin
M.
,
Liu
S.
,
Derry
J. M.
,
Jain
A.
.
2006
.
Impaired dendritic-cell function in ectodermal dysplasia with immune deficiency is linked to defective NEMO ubiquitination.
Blood
108
:
2324
2331
.
65
Brossart
P.
,
Zobywalski
A.
,
Grünebach
F.
,
Behnke
L.
,
Stuhler
G.
,
Reichardt
V. L.
,
Kanz
L.
,
Brugger
W.
.
2000
.
Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells.
Cancer Res.
60
:
4485
4492
.
66
Canning
M. O.
,
Grotenhuis
K.
,
de Wit
H.
,
Ruwhof
C.
,
Drexhage
H. A.
.
2001
.
1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes.
Eur. J. Endocrinol.
145
:
351
357
.
67
Lyakh
L. A.
,
Sanford
M.
,
Chekol
S.
,
Young
H. A.
,
Roberts
A. B.
.
2005
.
TGF-beta and vitamin D3 utilize distinct pathways to suppress IL-12 production and modulate rapid differentiation of human monocytes into CD83+ dendritic cells.
J. Immunol.
174
:
2061
2070
.
68
Penna
G.
,
Adorini
L.
.
2000
.
1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation.
J. Immunol.
164
:
2405
2411
.
69
Piemonti
L.
,
Monti
P.
,
Sironi
M.
,
Fraticelli
P.
,
Leone
B. E.
,
Dal Cin
E.
,
Allavena
P.
,
Di Carlo
V.
.
2000
.
Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells.
J. Immunol.
164
:
4443
4451
.
70
Piemonti
L.
,
Monti
P.
,
Allavena
P.
,
Sironi
M.
,
Soldini
L.
,
Leone
B. E.
,
Socci
C.
,
Di Carlo
V.
.
1999
.
Glucocorticoids affect human dendritic cell differentiation and maturation.
J. Immunol.
162
:
6473
6481
.
71
Woltman
A. M.
,
van der Kooij
S. W.
,
de Fijter
J. W.
,
van Kooten
C.
.
2006
.
Maturation-resistant dendritic cells induce hyporesponsiveness in alloreactive CD45RA+ and CD45RO+ T-cell populations.
Am. J. Transplant.
6
:
2580
2591
.